Preliminary study of the relationship between novel coronavirus pneumonia and liver function damage: a multicenter study
10.3760/cma.j.issn.1007-3418.2020.02.003
- VernacularTitle: 新型冠状病毒肺炎与肝功能损伤的关系初探：一项多中心研究
- Author:
Chuan LIU
1
;
Zicheng JIANG
2
;
Chuxiao SHAO
3
;
Hongguang ZHANG
4
;
Hongmei YUE
5
;
Zhenhuai CHEN
6
;
Baoyi MA
7
;
Weiying LIU
1
;
Huihong HUANG
2
;
Jie YANG
3
;
Yan WANG
8
;
Hongyan LIU
8
;
Dan XU
1
;
Jitao WANG
1
;
Junyan YANG
8
;
Hongqiu PAN
4
;
Shengqiang ZOU
4
;
Fujian LI
6
;
Junqiang LEI
1
;
Xun LI
1
;
Qing HE
9
;
Ye GU
8
;
Xiaolong QI
1
Author Information
1. COVID-19 study group, The First Hospital of Lanzhou University, Lanzhou 730000, China
2. COVID-19 study group, Ankang Central Hospital, Ankang 725000, China
3. COVID-19 study group, Lishui Central Hospital, Lishui 323000, China
4. COVID-19 study group, The Affiliated Third Hospital of Jiangsu University, Zhenjiang 212021, China
5. Department of Respiratory and Critical Care Medicine, The First Hospital of Lanzhou University, Lanzhou 730000, China
6. COVID-19 study group, The People's Hospital of Baoding, Baoding 071000, China
7. COVID-19 study group, The People’s Hospital of LinXia Hui Prefecture, Linxia 731100, China
8. COVID-19 study group, The Sixth People’s Hospital of Shenyang, Shenyang 110006, China
9. COVID-19 study group, The Third People's Hospital of Shenzhen, Shenzhen 518100, China
- Publication Type:Journal Article
- Keywords:
Liver function;
NCP;
Hypohepatia;
Clinical typing
- From:
Chinese Journal of Hepatology
2020;28(2):148-152
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To analyze the clinical characteristics of cases of novel coronavirus pneumonia and a preliminary study to explore the relationship between different clinical classification and liver damage.
Methods:Consecutively confirmed novel coronavirus infection cases admitted to seven designated hospitals during January 23, 2020 to February 8, 2020 were included. Clinical classification (mild, moderate, severe, and critical) was carried out according to the diagnosis and treatment program of novel coronavirus pneumonia (Trial Fifth Edition) issued by the National Health Commission. The research data were analyzed using SPSS19.0 statistical software. Quantitative data were expressed as median (interquartile range), and qualitative data were expressed as frequency and rate.
Results:32 confirmed cases that met the inclusion criteria were included. 28 cases were of mild or moderate type (87.50%), and four cases (12.50%) of severe or critical type. Four cases (12.5%) were combined with one underlying disease (bronchial asthma, coronary heart disease, malignant tumor, chronic kidney disease), and one case (3.13%) was simultaneously combined with high blood pressure and malignant tumor. The results of laboratory examination showed that the alanine aminotransferase (ALT), aspartate aminotransferase (AST), albumin (ALB), and total bilirubin (TBil) for entire cohort were 26.98 (16.88 ~ 46.09) U/L and 24.75 (18.71 ~ 31.79) U/L, 39.00 (36.20 ~ 44.20) g/L and 16.40 (11.34- ~ 21.15) mmol/L, respectively. ALT, AST, ALB and TBil of the mild or moderate subgroups were 22.75 (16.31- ~ 37.25) U/L, 23.63 (18.71 ~ 26.50) U/L, 39.70 (36.50 ~ 46.10) g/L, and 15.95 (11.34 ~ 20.83) mmol/L, respectively. ALT, AST, ALB and TBil of the severe or critical subgroups were 60.25 (40.88 ~ 68.90) U/L, 37.00 (20.88 ~ 64.45) U/L, 35.75 (28.68 ~ 42.00) g/L, and 20.50 (11.28 ~ 25.00) mmol/L, respectively.
Conclusion:The results of this multicenter retrospective study suggests that novel coronavirus pneumonia combined with liver damage is more likely to be caused by adverse drug reactions and systemic inflammation in severe patients receiving medical treatment. Therefore, liver function monitoring and evaluation should be strengthened during the treatment of such patients.
